Humacyte secures FDA approval for bioengineered vascular conduit SYMVESS
Humacyte's SYMVESS, a bioengineered vascular conduit, received FDA approval for treating extremity arterial injuries, offering an off-the-shelf alternative to autologous vein grafts, reducing surgical time and complications.
Highlighted Terms
Related News
Humacyte secures FDA approval for bioengineered vascular conduit SYMVESS
Humacyte's SYMVESS, a bioengineered vascular conduit, received FDA approval for treating extremity arterial injuries, offering an off-the-shelf alternative to autologous vein grafts, reducing surgical time and complications.